Literature DB >> 26755878

Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes.

Yuan-Chi Teng1, Zhao-Qing Shen1, Cheng-Heng Kao1, Ting-Fen Tsai1.   

Abstract

The multifactorial and multistage pathogenesis of hepatocellular carcinoma (HCC) has fascinated a wide spectrum of scientists for decades. While a number of major risk factors have been identified, their mechanistic roles in hepatocarcinogenesis still need to be elucidated. Many tumor suppressor genes (TSGs) have been identified as being involved in HCC. These TSGs can be classified into two groups depending on the situation with respect to allelic mutation/loss in the tumors: the recessive TSGs with two required mutated alleles and the haploinsufficient TSGs with one required mutated allele. Hepatitis B virus (HBV) is one of the most important risk factors associated with HCC. Although mice cannot be infected with HBV due to the narrow host range of HBV and the lack of a proper receptor, one advantage of mouse models for HBV/HCC research is the numerous and powerful genetic tools that help investigate the phenotypic effects of viral proteins and allow the dissection of the dose-dependent action of TSGs. Here, we mainly focus on the application of mouse models in relation to HBV-associated HCC and on TSGs that act either in a recessive or in a haploinsufficient manner. Discoveries obtained using mouse models will have a great impact on HCC translational medicine.

Entities:  

Keywords:  Haploinsufficiency; Hepatitis B virus; Hepatocellular carcinoma; Mouse models; Tumor suppressor genes

Mesh:

Year:  2016        PMID: 26755878      PMCID: PMC4698494          DOI: 10.3748/wjg.v22.i1.300

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  245 in total

1.  Late mitotic failure in mice lacking Sak, a polo-like kinase.

Authors:  J W Hudson; A Kozarova; P Cheung; J C Macmillan; C J Swallow; J C Cross; J W Dennis
Journal:  Curr Biol       Date:  2001-03-20       Impact factor: 10.834

2.  Reduced expression of CYLD in human colon and hepatocellular carcinomas.

Authors:  Claus Hellerbrand; Elisabeth Bumes; Frauke Bataille; Wolfgang Dietmaier; Ramin Massoumi; Anja K Bosserhoff
Journal:  Carcinogenesis       Date:  2006-06-13       Impact factor: 4.944

3.  Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice.

Authors:  K Nomoto; K Tsuneyama; H O Abdel Aziz; H Takahashi; Y Murai; Z-G Cui; M Fujimoto; I Kato; K Hiraga; D K Hsu; F-T Liu; Y Takano
Journal:  J Pathol       Date:  2006-12       Impact factor: 7.996

Review 4.  The cell cycle and cancer.

Authors:  Gareth H Williams; Kai Stoeber
Journal:  J Pathol       Date:  2011-10-28       Impact factor: 7.996

5.  Characterization of T-cell tolerance to hepatitis B virus (HBV) antigen in transgenic mice.

Authors:  H Takashima; K Araki; J Miyazaki; K Yamamura; M Kimoto
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

6.  Absence of the SRC-2 coactivator results in a glycogenopathy resembling Von Gierke's disease.

Authors:  Atul R Chopra; Jean-Francois Louet; Pradip Saha; Jie An; Franco Demayo; Jianming Xu; Brian York; Saul Karpen; Milton Finegold; David Moore; Lawrence Chan; Christopher B Newgard; Bert W O'Malley
Journal:  Science       Date:  2008-11-28       Impact factor: 47.728

7.  Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice.

Authors:  Masaaki Komatsu; Satoshi Waguri; Takashi Ueno; Junichi Iwata; Shigeo Murata; Isei Tanida; Junji Ezaki; Noboru Mizushima; Yoshinori Ohsumi; Yasuo Uchiyama; Eiki Kominami; Keiji Tanaka; Tomoki Chiba
Journal:  J Cell Biol       Date:  2005-05-02       Impact factor: 10.539

8.  The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo.

Authors:  Su-Ru Lin; Hung-Chih Yang; Yi-Ting Kuo; Chun-Jen Liu; Ta-Yu Yang; Ku-Chun Sung; You-Yu Lin; Hurng-Yi Wang; Chih-Chiang Wang; Yueh-Chi Shen; Fang-Yi Wu; Jia-Horng Kao; Ding-Shinn Chen; Pei-Jer Chen
Journal:  Mol Ther Nucleic Acids       Date:  2014-08-19       Impact factor: 10.183

9.  Hepatitis B virus X protein targets the Bcl-2 protein CED-9 to induce intracellular Ca2+ increase and cell death in Caenorhabditis elegans.

Authors:  Xin Geng; Brian L Harry; Qinghua Zhou; Riley Robert Skeen-Gaar; Xiao Ge; Eui Seung Lee; Shohei Mitani; Ding Xue
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-22       Impact factor: 11.205

Review 10.  The emerging role of hepatitis B virus pre-S2 deletion mutant proteins in HBV tumorigenesis.

Authors:  Ih-Jen Su; Lily Hui-Ching Wang; Wen-Chuan Hsieh; Han-Chieh Wu; Chiao-Fang Teng; Hung-Wen Tsai; Wenya Huang
Journal:  J Biomed Sci       Date:  2014-10-15       Impact factor: 8.410

View more
  10 in total

1.  The mechanism of apoliprotein A1 down-regulated by Hepatitis B virus.

Authors:  Yuanyuan Wang; Junli Hao; Xiaohong Liu; Hongxin Wang; Xin Zeng; Jing Yang; Lei Li; Xi Kuang; Tao Zhang
Journal:  Lipids Health Dis       Date:  2016-03-25       Impact factor: 3.876

2.  Dual oncogenic and tumor suppressor roles of the promyelocytic leukemia gene in hepatocarcinogenesis associated with hepatitis B virus surface antigen.

Authors:  Yih-Lin Chung; Mei-Ling Wu
Journal:  Oncotarget       Date:  2016-05-10

3.  Positive association between serum apolipoprotein M levels and hepatitis B virus DNA load in HBeAg-negative chronic hepatitis B.

Authors:  Ting Shen; Wei Min Wu; Wen Han Du; Lin Wang; La Gu He; Li Tan; ZeYou Wang; Ruohong Chen; Min Hu; Ya Ping Ren
Journal:  Lipids Health Dis       Date:  2016-12-07       Impact factor: 3.876

4.  Gene expression, regulation of DEN and HBx induced HCC mice models and comparisons of tumor, para-tumor and normal tissues.

Authors:  Qin Tang; Qi Wang; Qiong Zhang; Sheng-Yan Lin; Yanhong Zhu; Xiangliang Yang; An-Yuan Guo
Journal:  BMC Cancer       Date:  2017-12-18       Impact factor: 4.430

5.  Significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma: A care-compliant case report.

Authors:  Young-Hsiang Lin; Shih-Kai Hung; Wen-Yen Chiou; Moon-Sing Lee; Bing-Jie Shen; Liang-Cheng Chen; Dai-Wei Liu; Wei-Ta Tsai; Po-Hao Lin; Yi-Ting Shih; Feng-Chun Hsu; Shiang-Jiun Tsai; Michael W Y Chan; Hon-Yi Lin
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

6.  Promotive action of 2-acetylaminofluorene on hepatic precancerous lesions initiated by diethylnitrosamine in rats: Molecular study.

Authors:  Amany Helmy Hasanin; Eman K Habib; Nesreen El Gayar; Marwa Matboli
Journal:  World J Hepatol       Date:  2021-03-27

Review 7.  Role of hepatitis c virus in hepatocellular carcinoma and neurological disorders: an overview.

Authors:  Mohd Suhail; Sayed Sartaj Sohrab; Mohammad Amjad Kamal; Esam Ibraheem Azhar
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

8.  Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model.

Authors:  Sharon Wei Ling Lee; Giulia Adriani; Erica Ceccarello; Andrea Pavesi; Anthony Tanoto Tan; Antonio Bertoletti; Roger Dale Kamm; Siew Cheng Wong
Journal:  Front Immunol       Date:  2018-03-06       Impact factor: 7.561

Review 9.  Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment.

Authors:  Zuzana Macek Jilkova; Keerthi Kurma; Thomas Decaens
Journal:  Cancers (Basel)       Date:  2019-10-02       Impact factor: 6.639

Review 10.  The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials.

Authors:  Carmine Izzo; Monica Annunziata; Giuseppe Melara; Roberta Sciorio; Marcello Dallio; Mario Masarone; Alessandro Federico; Marcello Persico
Journal:  Nutrients       Date:  2021-03-13       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.